NASDAQ · Medical - Diagnostics & Research

ACRS (ACRS) Stock

$6.18 +2.66% NASDAQ: ACRS Healthcare

Valuation

MetricValue
Price$6.18
Market Cap$863.12M
P/E Ratio-10.35
P/B Ratio6.88
P/S Ratio102.04
EPS (TTM)$-0.53
52-Week High$6.54
52-Week Low$1.34
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-61.65%
ROA-42.15%
ROCE-56.99%
Gross Margin-950.00%
Operating Margin-950.00%
Net Margin-921.50%
Debt/Equity0.02
Current Ratio5.21

Annual Financials (USD)

Metric20212022202320242025
Revenue$7.0M$30.0M$31.0M$19.0M$8.0M
Operating Profit$-90.0M$-90.0M$-97.0M$-142.0M$-76.0M
Net Profit$-91.0M$-87.0M$-88.0M$-132.0M$-65.0M
EPS$-1.60$-1.33$-1.27$-1.71$-0.53
Op Margin-1327.1%-302.0%-311.6%-758.2%-975.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$251.0M$255.0M$197.0M$220.0M$160.0M
Total Liabilities$54.0M$57.0M$40.0M$65.0M$57.0M
Cash$27.0M$45.0M$40.0M$25.0M$20.0M
Borrowings$1.0M$1.0M$0$0$2.0M

Latest News

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? Zacks · Jul 1, 2026 3 Penny Stocks Under $5 Backed by Real Revenue Growth MarketBeat · Jun 20, 2026 Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On Insider Monkey · Jun 7, 2026 Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 MarketBeat · Jun 4, 2026 Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-52.0M$-68.0M$-78.0M$-20.0M$-47.0M
Investing Cash Flow$-168.0M$12.0M$45.0M$-70.0M$48.0M
Financing Cash Flow$-2.0M$0$0$0$-6.0M
Net Cash Flow$5.0M$18.0M$-5.0M$-15.0M$-5.0M
Free Cash Flow$-52.0M$-68.0M$-80.0M$-20.0M$-47.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.23
EV / EBITDA-10.91
FCF Yield-7.41%
Quick Ratio3.46
Interest Coverage0.00
Return 1Y226.19%
Return 3Y-44.37%
Return 5Y-64.09%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLO $1.98 -0.25% -2.17 $683.41M 0.00%
BIOA $9.73 +2.21% -9.34 $366.33M 0.00%
CABA $3.57 +8.18% -2.23 $582.11M 0.00%
EDIT $3.08 +0.33% -1.39 $472.66M 0.00%
MASS $10.33 -3.00% 12.81 $423.81M 0.00%

About ACRS

ACRS is led by CEO Neal S. Walker, employs 61 people, headquartered in US, publicly traded since 2015.

ACRS stock trades at $6.18 with a market capitalization of $863.12M. The stock is valued at a price-to-earnings (P/E) ratio of -10.35, price-to-book of 6.88, price-to-sales of 102.04. Over the past 52 weeks the stock has ranged between $1.34 and $6.54, and currently trades 5.5% below its 52-week high.

On profitability, ACRS generates a return on equity (ROE) of -61.65%, return on capital employed of -56.99%, an operating margin of -950.00%, a net profit margin of -921.50%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% NVS Drug Manufacturers - General $162.46 +0.75% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.77 +3.66% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides